BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Gemcitabine: trial readouts and FDA decisions
16 upcoming industry Phase 2/3 readout(s) in the next 90 days, 0 upcoming FDA event(s), 17 readout(s) in the last 180 days and 0 FDA event(s) in the last 12 months. Sponsors: AstraZeneca, Gilead Sciences, Sichuan Baili Pharmaceutical Co., Ltd., BeyondBio Inc., SynerGene Therapeutics, Inc., Karyopharm Therapeutics Inc, GC Cell Corporation, Janssen Research & Development, LLC, SynerGene Therapeutics, Inc., Janssen Research & Development, LLC, Suzhou Suncadia Biopharmaceuticals Co., Ltd., Akeso, RemeGen Co., Ltd., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., CStone Pharmaceuticals, Seagen, a wholly owned subsidiary of Pfizer, Merck Sharp & Dohme LLC, Grit Biotechnology, ImmunityBio, Inc., Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd., Sichuan Baili Pharmaceutical Co., Ltd., Astellas Pharma Global Development, Inc., Verastem, Inc., TJ Biopharma Co., Ltd., Panbela Therapeutics, Inc., Genmab, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd., Boehringer Ingelheim, Prestige Biopharma Limited, Qilu Pharmaceutical Co., Ltd., Revolution Medicines, Inc.. Drug names come from ClinicalTrials.gov intervention names and FDA records, lightly normalised; one drug can appear under several names (code, generic, brand).
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-30 est. | P1/P2 | BeyondBio Inc. | NCT03579836 Evaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer | Locally Advanced or Metastatic Pancreatic Cancer | recruiting | 75 |
| 2026-12 est. | P2 | SynerGene Therapeutics, Inc. | NCT02340117 Study of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer | Metastatic Pancreatic Cancer | active not recruiting | 28 |
| 2026-12 est. | P2/P3 | Karyopharm Therapeutics Inc KPTIQ | NCT04442022 A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma | Relapsed/Refractory Diffuse Large B-cell Lymphoma | active not recruiting | 501 |
| 2026-12 est. | P3 | Gilead Sciences GILD | NCT04639986 Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC) | Metastatic Breast Cancer | active not recruiting | 331 |
| 2026-12 est. | P3 | GC Cell Corporation | NCT04969731 Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer | Pancreatic Ductal Adenocarcinoma | recruiting | 408 |
| 2026-12-30 est. | P3 | Janssen Research & Development, LLC | NCT04658862 A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder | Urinary Bladder Neoplasms | active not recruiting | 518 |
| 2026-12-30 est. | P2 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | NCT06465563 SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer | Biliary Tract Cancer | active not recruiting | 93 |
| 2026-12-31 est. | P1/P2 | Akeso | NCT05229497 A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors | Advanced Malignant Tumors | active not recruiting | 154 |
| 2026-12-31 est. | P3 | RemeGen Co., Ltd. | NCT05302284 A Study of RC48-ADC Combined With Toripalimab For First-line Treatment of Urothelial Carcinoma | Urothelial Carcinoma; HER2-expressing | recruiting | 452 |
| 2026-12-31 est. | P3 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. SKBBY | NCT06081959 Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer | Metastatic Breast Cancer | recruiting | 376 |
| 2027-01 est. | P1/P2 | CStone Pharmaceuticals | NCT06741644 A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors | Advanced Solid Tumors | recruiting | 800 |
| 2027-01-29 est. | P3 | Seagen, a wholly owned subsidiary of Pfizer | NCT05911295 Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2 | Urothelial Carcinoma | active not recruiting | 412 |
| 2027-01-31 est. | P3 | Merck Sharp & Dohme LLC MRK | NCT04241185 Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-99 | Urinary Bladder Neoplasms | active not recruiting | 520 |
| 2027-01-31 est. | P2 | Grit Biotechnology | NCT06241781 Autologous Tumor Infiltrating Lymphocytes Injection (GT101 Injection) for the Treatment of Recurrent or Metastatic Cervical Cancer | Recurrent or Metastatic Cervical Cancer | recruiting | 100 |
| 2027-02 est. | P3 | Gilead Sciences GILD | NCT05382286 Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Ad | Triple Negative Breast Cancer; PD-L1 Positive | active not recruiting | 443 |
| 2026-12-30 est. | P1/P2 | Akeso | NCT06646055 AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer | Metastatic Pancreatic Ductal Adenocarcinoma | active not recruiting | 110 |
Readouts, last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-11-17 est. | P2 | AstraZeneca AZN | NCT06219941 AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2 | Gastric Cancer; Gastroesophageal Junction Cancer; Biliary Tract Cancer; Pancreatic Ductal Adenocarci | recruiting | 226 |
| 2026-11 est. | P2 | ImmunityBio, Inc. IBRX | NCT06829823 Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer | Non-muscle Invasive Bladder Cancer (NMIBC) | not yet recruiting | 20 |
| 2026-11 est. | P2 | Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | NCT06767813 Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms | Pancreatic Neoplasms | recruiting | 80 |
| 2026-11 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06118333 A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma(PANKU-NPC01) | Nasopharyngeal Carcinoma | active not recruiting | 386 |
| 2026-10-31 est. | P2 | Astellas Pharma Global Development, Inc. | NCT03816163 A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | Pancreatic Cancer; Metastatic Pancreatic Cancer; Metastatic Pancreatic Adenocarcinoma | active not recruiting | 393 |
| 2026-10-27 est. | P2 | AstraZeneca AZN | NCT05775159 Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Hepatocellular Carcinoma; Biliary Tract Cancer | active not recruiting | 294 |
| 2026-08-31 est. | P1/P2 | Verastem, Inc. VSTM | NCT05669482 Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer | KRAS Activating Mutation; Metastatic Cancer; Pancreas Cancer; Neoplasms Pancreatic; Malignant Neopla | active not recruiting | 40 |
| 2026-08-30 est. | P2 | TJ Biopharma Co., Ltd. | NCT07005336 A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Loca | Non Small Cell Lung Cancer | active not recruiting | 150 |
| 2026-08-29 est. | P2/P3 | Panbela Therapeutics, Inc. | NCT05254171 Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer | Pancreatic Cancer Metastatic; Pancreatic Ductal Adenocarcinoma; Pancreatic Cancer Stage IV | recruiting | 600 |
| 2026-08-18 | P3 | Genmab GMAB | NCT06619236 Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Platinum-resistant Ovarian Cancer | active not recruiting | 584 |
| 2026-08-18 est. | P3 | Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. | NCT06519370 FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer | Triple Negative Breast Cancer | active not recruiting | 350 |
| 2026-08 est. | P3 | Sichuan Baili Pharmaceutical Co., Ltd. | NCT06343948 A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic HR+HER2- Breast Canc | HR+HER2- Breast Cancer | active not recruiting | 383 |
| 2026-07-03 est. | P3 | Boehringer Ingelheim | NCT06370871 Brightline-3: A Study to Find Out Whether Brigimadlin in Combination With Ezabenlimab Helps People With Advanced Soft Tissue Sarcoma | Advanced Soft Tissue Sarcoma; Undifferentiated Pleomorphic Sarcoma (UPS); Myxofibrosarcoma (MFS) | withdrawn | |
| 2026-07 est. | P1/P2 | Prestige Biopharma Limited PBH | NCT05141149 First in Human Phase1/2a Clinical Trial of Anti-PAUF Monoclonal Antibody PBP1510 in Patients With Pancreatic Cancer | Pancreatic Cancer | active not recruiting | 80 |
| 2026-06-30 est. | P2 | Qilu Pharmaceutical Co., Ltd. | NCT06446388 Study of QLS31905 and/or QL1706 Combination With Chemotherapy in the Advanced Malignant Solid Tumors | Advanced Solid Tumor | not yet recruiting | 360 |
| 2026-06-01 | P3 | AstraZeneca AZN | NCT03682068 Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable | Unresectable Locally Advanced Urothelial Cancer; Metastatic Urothelial Cancer | active not recruiting | 1246 |
| 2026-06 est. | P3 | Revolution Medicines, Inc. RVMD | NCT06625320 Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer; PDAC; PDAC - Pancreatic Ductal Adenocarcinoma | active not recruiting | 500 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.